GCAN Greater Cannabis Company Inc (PK)

Specialists in Life Sciences Industry with Track Record of Consummating Successful M&A and Corporate Transactions to Assist Company in Achieving Strategic Objectives Gammacan International (OTCBB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that it has engaged Global Markets Capital Corporation ("GMCG"), an independent investment bank focused in the life sciences industry and specializing in structuring and executing corporate transactions, to assist the Company in achieving its strategic objective of partnering with leaders in the blood, plasma and IVIg markets. "We believe that the development of IVIg based products for the treatment of metastatic cancer have advanced to a stage that Gammacan is ready to explore various options of key synergistic "partnerships" with IVIg manufacturers, plasma collectors, and other players in the plasma industry," stated Vered Caplan, CEO. Mark R. Saunders, President of Global Markets Capital Group, LLC, stated, "Global Markets Capital Group is extremely pleased to work with Gammacan, an emerging leader in the IVIg field. We look forward to support Gammacan through strategic transactions that will further the Company's efforts to develop and commercialize its products and that will provide them with greater exposure in the capital markets." About Global Markets Capital Group Global Markets Capital Group, LLC (GMCG, LLC) is a New York based independent investment banking firm with offices in Sydney, Australia that provides innovative strategic advisory services and mergers and acquisitions expertise globally to public and private life science companies. Global Markets Capital Group currently represents a number of the leading life science companies in the US and Europe, as well as a large number of the leading publicly traded life science companies in Australia. For further information on Global Markets Capital Group visit www.globalmarketscapital.com. About Gammacan: Gammacan is focusing on the commercialization of a revolutionary anti-cancer immunotherapy that the Company believes will be proven to be effective in reducing the metastatic spread of a wide range of cancers. Gammacan's proposed treatment is based on IVIg, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. It works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. Approximately twenty companies produce IVIg, and annual worldwide sales are currently in excess of 50 metric tones with an estimated value in excess of 1.5 billion USD. IVIg is commonly used to treat certain autoimmune diseases and blood disorders and to replace the antibodies in people who are unable to produce them. For more information about Gammacan visit www.gammacan.com or call the company's headquarters in Givat Shmuel, Israel at 972 3 5774475. Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding: the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, inability to hire appropriate staff to develop the technology, unforeseen technical difficulties in developing the technology, inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early stage medical research and development companies filed with the SEC on Edgar.